What is the treatment for a patient with a beta blocker overdose, particularly one who is hemodynamically unstable with bradycardia and hypotension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 22, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Beta-Blocker Overdose

For hemodynamically unstable patients with beta-blocker overdose presenting with bradycardia and hypotension, initiate high-dose insulin euglycemia therapy (1 U/kg bolus with 0.5 g/kg dextrose, then 1 U/kg/hour infusion) and IV glucagon (3-10 mg bolus over 3-5 minutes, then 3-5 mg/hour infusion) as first-line pharmacologic interventions, with ECMO reserved for refractory shock. 1, 2

Immediate Stabilization

  • Establish continuous cardiac monitoring, secure IV access (preferably central if prolonged therapy anticipated), and assess airway protection following standard BLS/ACLS protocols 1, 2
  • Obtain baseline labs including glucose, potassium, ionized calcium, and renal function 1
  • Consider activated charcoal (1-2 g/kg) if presentation is within 1-2 hours of ingestion and airway is protected 1

First-Line Pharmacologic Therapy

The American College of Cardiology and American Heart Association provide Class 2a recommendations for both high-dose insulin and glucagon as reasonable first-line therapies for refractory shock 1, 2:

High-Dose Insulin Euglycemia Therapy (HIET)

  • Administer 1 U/kg regular insulin IV bolus with simultaneous 0.5 g/kg dextrose bolus 1, 2
  • Follow with continuous infusion of 1 U/kg/hour insulin (range 0.5-1 U/kg/hour) 1
  • Co-administer dextrose infusion (0.5 g/kg/hour) to maintain euglycemia 1
  • HIET is the most effective therapy for restoring hemodynamic stability in severe beta-blocker toxicity by improving myocardial contractility and cardiac output 1, 3
  • Monitor glucose every 15 minutes initially, then hourly once stable, targeting 100-250 mg/dL 1, 2
  • Monitor potassium levels closely as hypokalemia is a common adverse effect 1, 3

Glucagon

  • Administer 3-10 mg IV bolus over 3-5 minutes, followed by continuous infusion of 3-5 mg/hour 1, 2
  • Glucagon bypasses blocked beta-adrenergic receptors by directly activating hepatic adenyl cyclase, increasing heart rate and myocardial contractility independent of beta-receptor status 1, 4
  • Extensive clinical experience shows consistent increases in heart rate during beta-blocker overdose 1, 4
  • Monitor for nausea and vomiting, which are common side effects 1
  • Be aware of potential tachyphylaxis with prolonged use 1

Second-Line Therapies

Vasopressor Support

  • Use norepinephrine to increase blood pressure in vasoplegic shock 1, 2
  • Use epinephrine to increase contractility and heart rate 1, 2
  • Catecholamines and vasopressors are associated with reduced mortality and improved hemodynamics in beta-blocker toxicity 3

Calcium Administration

  • The American Heart Association gives calcium a Class 2b recommendation for beta-blocker overdose (weaker evidence compared to calcium channel blocker toxicity) 1, 2
  • May be considered in refractory shock, though evidence is limited 2

Rescue Therapy for Refractory Cases

Extracorporeal Membrane Oxygenation (ECMO)

  • Consider veno-arterial ECMO for shock refractory to all pharmacological interventions (Class 2b recommendation from the American College of Cardiology) 1, 2
  • ECMO is associated with improved survival in patients with severe cardiogenic shock or cardiac arrest from beta-blocker overdose 3
  • Recent consensus from the American Heart Association supports ECMO for refractory shock from reversible causes such as drug toxicity 2

Critical Monitoring Parameters

  • Continuous cardiac telemetry for rhythm and conduction abnormalities 1
  • Arterial line for blood pressure monitoring in shock states 1
  • Glucose monitoring every 15 minutes initially during HIET, then hourly once stable 1, 2
  • Potassium levels monitored closely during HIET 1, 3
  • Ionized calcium levels if calcium infusions are used 1

Common Pitfalls to Avoid

  • Do not underdose glucagon - use the full 3-10 mg bolus, not the typical 1-2 mg doses used for hypoglycemia 1
  • Do not delay escalation to high-dose insulin if initial therapies are failing 1
  • Avoid lipid emulsion therapy - evidence shows variable and inconsistent response in beta-blocker overdose 1, 3
  • Do not abruptly withdraw beta-blocker therapy in patients on chronic therapy, as this can lead to clinical deterioration 2

Treatment Algorithm

  1. Immediate stabilization: Cardiac monitoring, IV access, airway assessment 1, 2
  2. First-line: Initiate both high-dose insulin (1 U/kg bolus + infusion) AND glucagon (3-10 mg bolus + infusion) simultaneously 1, 2
  3. If refractory: Add vasopressor support (norepinephrine/epinephrine) 1, 2
  4. If still refractory: Consider calcium administration 1, 2
  5. If shock persists: Initiate ECMO 1, 2

Special Considerations

  • Prompt consultation with a medical toxicologist or poison control center (1-800-222-1222) is strongly recommended for all beta-blocker overdoses 1
  • For water-soluble beta-blockers like atenolol, hemodialysis may assist in massive overdoses by improving elimination, though survival benefit is not established 3
  • Temporary overdrive cardiac pacing may be useful for preventing arrhythmias in sotalol toxicity specifically 3

References

Guideline

Management of Beta-Blocker Overdose

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Treatment for Beta Blocker Overdose

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Treatment for beta-blocker poisoning: a systematic review.

Clinical toxicology (Philadelphia, Pa.), 2020

Research

Successful resuscitation and survival following massive overdose of metoprolol.

The British journal of clinical practice, 1990

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.